Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning

Journal of Clinical Oncology

Volumn 26, Issue 35, 2008, Pages 5767-5774

  Armand, Philippe ^a   Gannamaneni, Supriya ^a   Kim, Haesook T ^a   Cutler, Corey S ^a   Ho, Vincent T ^a   Koreth, John ^a   Alyea, Edwin P ^a   LaCasce, Ann S ^a   Jacobsen, Eric D ^a   Fisher, David C ^a   Brown, Jennifer R ^a   Canellos, George P ^a   Freedman, Arnold S ^a   Soiffer, Robert J ^a   Antin, Joseph H ^a  

^a CAMBRIDGE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; MELPHALAN; METHOTREXATE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; INCIDENCE; LOADING DRUG DOSE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; PRIORITY JOURNAL; PROPHYLAXIS; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; BOSTON; CALCINEURIN; DISEASE-FREE SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIERS ESTIMATE; LYMPHOMA; METHOTREXATE; MIDDLE AGED; RETROSPECTIVE STUDIES; SIROLIMUS; TIME FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 57449092086     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.17.7279     Document Type: Article

References (31)

1. Sehgal SN: Sirolimus: Its discovery, biological properties, and mechanism of action. Transplant Proc 35:7S-14S, 2003 (suppl)
2. Sehgal SN: Rapamune (RAPA, rapamycin, sirolimus): Mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 31:335-340, 1998
3. Mehrabi A, Fonouni H, Kashfi A, et al: The role and value of sirolimus administration in kidney and liver transplantation. Clin Transplant 20:30-43, 2006 (suppl 17)
4. Benito AI, Furlong T, Martin PJ, et al: Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation 72: 1924-1929, 2001
5. Johnston LJ, Brown J, Shizuru JA, et al: Rapamycin (sirolimus) for treatment of chronic graftversus-host disease. Biol Blood Marrow Transplant 11:47-55, 2005
6. Couriel DR, Saliba R, Escalon MP, et al: Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. Br J Haematol 130:409-417, 2005
7. Jurado M, Vallejo C, Perez-Simon JA, et al: Sirolimus as part of immunosuppressive therapy for refractory chronic graft-versus-host disease. Biol Blood Marrow Transplant 13:701-706, 2007
8. Antin JH, Kim HT, Cutler C, et al: Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood 102:1601-1605, 2003
9. Cutler C, Li S, Ho VT, et al: Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood 109:3108-3114, 2007
10. Cutler C, Kim HT, Hochberg E, et al: Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 10: 328-336, 2004
11. Costa LJ: Aspects of mTOR biology and the use of mTOR inhibitors in non-Hodgkin's lymphoma. Cancer Treat Rev 33:78-84, 2007
12. Decker T, Hipp S, Ringshausen I, et al: Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin. Blood 101:278-285, 2003
13. Jundt F, Raetzel N, Muller C, et al: A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein {beta} and NF-{kappa}B activity in Hodgkin and anaplastic large cell lymphomas. Blood 106:1801-1807, 2005
14. Wanner K, Hipp S, Oelsner M, et al: Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab. Br J Haematol 134:475-484, 2006
15. Sin SH, Roy D, Wang L, et al: Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling. Blood 109:2165-2173, 2007
16. Vaysberg M, Balatoni CE, Nepomuceno RR, et al: Rapamycin inhibits proliferation of Epstein-Barr virus-positive B-cell lymphomas through modulation of cell-cycle protein expression. Transplantation 83: 1114-1121, 2007
17. Brown VI, Fang J, Alcorn K, et al: Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling. Proc Natl Acad Sci U S A 100:15113-15118, 2003
18. Teachey DT, Obzut DA, Cooperman J, et al: The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood 107:1149-1155, 2006
19. Haritunians T, Mori A, O'Kelly J, et al: Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia 21:333-339, 2007
20. Witzig TE, Geyer SM, Ghobrial I, et al: Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 23: 5347-5356, 2005
21. Reeder CB, Gornet MK, Habermann TM, et al: A phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed aggressive non-Hodgkin lymphoma (NHL). Blood 110:121a, 2007 (abstr)
22. Johnston PB, Ansell SM, Colgan JP, et al: MTOR inhibition for relapsed or refractory Hodgkin lymphoma: Promising single agent activity with everolimus (RAD001). Blood 110:2555a, 2007 (abstr)
23. Ghobrial IM, Leduc R, Nelson M, et al: Phase II trial of the oral mTOR inhibitor RAD001 (everolimus) in relapsed and/or refractory Waldenstrom macroglobulinemia: Preliminary results. Blood 110: 4496a, 2007 (abstr)
24. Przepiorka D, Weisdorf D, Martin P, et al: 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15:825-828, 1995
25. Gray R: A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1140-1154, 1988
26. Fine J, Gray R: A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496-509, 1999
27. Marty FM, Bryar J, Browne SK, et al: Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: A cohort analysis. Blood 110:490-500, 2007
28. Sureda A, Robinson S, Canals C, et al: Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: An analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 26:455-462, 2008
29. Sorror ML, Storer BE, Maloney DG, et al: Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood 111:446-452, 2008
30. Cutler C, Miklos D, Kim HT, et al: Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 108:756-762, 2006
31. Gómez-Almaguer D, Ruiz-Arguelles GJ, del Carmen Tarin-Arzaga L, et al: Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 14:10-15, 2008